Intel has lost 65% in value since 2021 and has suspended its dividend. Intel's core x86 CPU business is losing market share to AMD, while Intel's gross margin is also far behind its peers. Intel's new leadership faces urgent decisions to avoid falling further behind competitors like AMD, NVIDIA, and TSMC in key growth markets.
Cosmos Health Strengthens Management Team with the Appointment of Veteran Executive Dimitris Moraitis as Vice President of Strategy & Operations — Neutral
COSM Accesswire — February 10, 2025CHICAGO, IL / ACCESS Newswire / February 10, 2025 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today the appointment of Dimitris Moraitis as Vice President of Strategy & Operations. Mr. Moraitis brings over 25 years of experience in strategic planning, operations, and business development within the pharmaceutical sector.
Contact Levi & Korsinsky by March 25, 2025 Deadline to Join Class Action Against Novo Nordisk A/S (NVO) — Neutral
NVO Accesswire — February 10, 2025NEW YORK, NY / ACCESS Newswire / February 10, 2025 / If you suffered a loss on your Novo Nordisk A/S (NYSE:NVO) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/novo-nordisk-a-s-lawsuit-submission-form?prid=128404&wire=1 or contact Joseph E. Levi, Esq.
Is Costco Wholesale Stock a Buy, Sell, or Hold in 2025? — Positive
COST The Motley Fool — February 10, 2025Bulk-buying, bargain-hunting shoppers propelled Costco Wholesale (COST -0.57%) to a record-breaking 2024 for sales and earnings. The discount retailer is benefiting from a resilient economic backdrop while capitalizing on an ongoing e-commerce expansion.
Lead Plaintiff Deadline Approaching in CROX: Kessler Topaz Meltzer & Check, LLP Has Filed a Securities Fraud Class Action Against Crocs, Inc. — Neutral
CROX Accesswire — February 10, 2025RADNOR, PA / ACCESS Newswire / February 10, 2025 / The law firm of Kessler Topaz Meltzer & Check, LLP informs investors that the firm has filed a securities fraud class action lawsuit against Crocs, Inc. (NASDAQ:CROX) ("Crocs" or the "Company") on behalf of investors who purchased or otherwise acquired Crocs common stock between November 3, 2022, and October, 28 2024, inclusive (the "Class Period"). This action, captioned Carretta v.
Shares of tech giant Qualcomm Inc. NASDAQ: QCOM have been stuck in a holding pattern for months, but recent signs point to a shift in momentum. After a largely sideways trend since July, the stock has gained 10% since December.
Take-Two Interactive CEO Strauss Zelnick on Grand Theft Auto VI: We couldn't be more excited — Positive
TTWO CNBC Television — February 10, 2025Take-Two Interactive chairman and CEO Strauss Zelnick joins 'Squawk Box' to discuss the company's quarterly earnings results, state of gaming, gaming release pipeline, regulatory and M&A outlook under the new Trump administration, latest news on Grand Theft Auto VI, impact of AI on gaming, and more.
Walmart Grocery Market Share to Increase with Rising Demand for Digital Shopping and Value-Oriented Options — Neutral
WMT GlobeNewsWire — February 10, 2025The report covers Walmart's US sales trends and e-commerce performance from fiscal years 2019 to 2024, and provides estimates of Walmart's US grocery market share from 2021 to 2024. It analyzes the reasons behind and implications of shifts in consumer perceptions and behaviors, highlighting future market opportunities. The report covers Walmart's US sales trends and e-commerce performance from fiscal years 2019 to 2024, and provides estimates of Walmart's US grocery market share from 2021 to 2024. It analyzes the reasons behind and implications of shifts in consumer perceptions and behaviors, highlighting future market opportunities.
2 Stocks to Shield Your Portfolio from AI and Tech Froth — Neutral
PM XOM MarketBeat — February 10, 2025In the current state of the stock market, investors argue over whether valuations are too high. Some see historical indicators as signs of doom, while others feel that future earnings will justify prices.
MGPI Stockholders Have Opportunity to Lead MGP Ingredients, Inc. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today! — Neutral
MGPI Accesswire — February 10, 2025NEW YORK CITY, NY / ACCESS Newswire / February 10, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against MGP Ingredients, Inc. ("MGP Ingredients" or "the Company") (NASDAQ:MGPI) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired MGP Ingredients securities between May 3, 2023 and October 30, 2024, both dates inclusive (the "Class Period").
Hain Celestial Reports Fiscal Second Quarter 2025 Financial Results — Neutral
HAIN GlobeNewsWire — February 10, 2025Strong Operating Cash Flow and Reduction in Debt; Positioned to Pivot to Growth in Back Half Exploring Strategic Options for Personal Care Category
BioCryst to Report Fourth Quarter 2024 Financial Results on February 24 — Neutral
BCRX GlobeNewsWire — February 10, 2025RESEARCH TRIANGLE PARK, N.C., Feb. 10, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its fourth quarter 2024 financial results on Monday, February 24, 2025.
Roivant Reports Financial Results for the Third Quarter Ended December 31, 2024, and Provides Business Update — Neutral
ROIV GlobeNewsWire — February 10, 2025BASEL, Switzerland and LONDON and NEW YORK, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today reported its financial results for the third quarter ended December 31, 2024, and provided a business update. Brepocitinib to be developed in third indication, cutaneous sarcoidosis (CS), an orphan indication with high unmet need; Phase 2 study initiation expected in second quarter of calendar year with topline data in second half of calendar year 2026 IMVT-1402 development is rapidly progressing with six Investigational New Drug (IND) applications cleared and pivotal studies in Graves' disease (GD) and difficult-to-treat rheumatoid arthritis (D2T RA) initiated Batoclimab …
Orion Group Holdings Awarded $211.7 Million in New Contracts — Neutral
ORN GlobeNewsWire — February 10, 2025HOUSTON, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Orion Group Holdings, Inc. (NYSE: ORN) (the “Company”, “Orion”), a leading specialty construction company, today announced new Marine and Concrete awards for a total value of approximately $211.7 million. These projects are expected to begin in 2025 with varying completion dates extending through 2026. These awards further reinforce Orion's position as a leader in specialized Marine and Concrete construction.
REGN SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Regeneron Pharmaceuticals, Inc. Investors Have Opportunity to Lead Class Action Lawsuit! — Neutral
REGN Accesswire — February 10, 2025NEW YORK CITY, NY / ACCESS Newswire / February 10, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. ("Regeneron" or "the Company") (NASDAQ:REGN) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Regeneron securities between November 2, 2023 and October 30, 2024, both dates inclusive (the "Class Period").
MU INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Micron Technology, Inc. Investors Have Opportunity to Lead Class Action Lawsuit! — Neutral
MU Accesswire — February 10, 2025NEW YORK CITY, NY / ACCESS Newswire / February 10, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Micron Technology, Inc. ("Micron" or "the Company") (NASDAQ:MU) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Micron securities between September 28, 2023 and December 18, 2024, both dates inclusive (the "Class Period").
AZN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that AstraZeneca PLC Shareholders with Losses Have Opportunity to Lead Class Action Lawsuit! — Neutral
AZN Accesswire — February 10, 2025NEW YORK CITY, NY / ACCESS Newswire / February 10, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against AstraZeneca PLC ("AstraZeneca" or "the Company") (NASDAQ:AZN) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired AstraZeneca securities between February 23, 2022 and December 17, 2024, both dates inclusive (the "Class Period").
RIG INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Transocean Ltd. Stockholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! — Neutral
RIG Accesswire — February 10, 2025NEW YORK, NY / ACCESS Newswire / February 10, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Transocean Ltd. ("Transocean" or "the Company") (NYSE:RIG) and certain of its officers.
NSM Named Exclusive Distributor of Ekso Indego® Personal Within the CRT Industry — Neutral
EKSO GlobeNewsWire — February 10, 2025Move expected to broaden access to Ekso Bionics' portable exoskeleton device for individuals living with spinal cord injuries and other mobility challenges across the United States Move expected to broaden access to Ekso Bionics' portable exoskeleton device for individuals living with spinal cord injuries and other mobility challenges across the United States
Incyte Reports 2024 Fourth Quarter and Year-End Financial Results, Provides 2025 Financial Guidance and Highlights 2025 R&D Milestones — Neutral
INCY Business Wire — February 10, 2025WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Reports 2024 Fourth Quarter and Year-End Financial Results, Provides 2025 Financial Guidance and Highlights 2025 R&D Milestones.